

**Redefinition of the (I) antimicrobial susceptibility category.**

**Commencing September 2021**

**Background:**

Antimicrobial susceptibility testing (AST) guide clinicians in the choice of antimicrobial to utilise in patients with a confirmed infection.

Clinicians will be aware of legacy AST categorisations:

- (S) Susceptible: antimicrobial may be utilised to treat the infection.
- (I) Intermediate: antimicrobial may be unsuccessful in the treatment of infection, recommend avoid.
- (R) Resistant: antimicrobial should not be used to treat the infection as likelihood of treatment failure.

EUCAST (the European Committee on Antimicrobial Susceptibility) has reviewed this reporting to reflect the fact that:

- For some organisms labelled as (I) for a particular antibiotic, use of a higher dosing regimen will likely effectively treat the infection\*
- Increasing levels of antibiotic resistance to standard dosing regimens for some organisms

**In light of this, as of September 2021, (I) will now be re-categorised with a new definition**

**(S) Susceptible:** antimicrobial can be used at standard dosing to treat the infection.

**(I) Susceptible, increased exposure:** likelihood of therapeutic success with use of a higher dosing regimen\*

**(R) Resistant:** antimicrobial should not be used to treat the infection.

*\*(with multifactorial factors that may determine treatment success including: site of infection, antibiotic dose, duration and route of administration)*

**How will it impact my clinical practices?**

- You may notice more (I) results in clinical reports.
- If an antibiotic with susceptibility reported as (I) is intended for use, then a high dosing regimen is indicated *(taking into consideration patients renal and liver function. If there are any queries or safety concerns about use of high dosing regimens in certain patients, please discuss with pharmacist/Duty Microbiologist.)*
- Oral and IV antibiotics exhibit different bioavailability characteristics. This means some bacteria may be effectively treated with a standard dose of IV antibiotics, but require a high-dose regimen of the oral equivalent (please refer to the attached section '**Standard and High dose antibiotic dosing regimens**' for further information)

**Why does this change need to occur?**

- Increasing levels of antibiotic resistance to standard dosing regimens.
- Recognition that, for some organisms, low-level resistance can be overcome by increasing the dosage of some antibiotics.
- All UK laboratories are required to change to this new definition.

**Where can I find out more information?**

- [https://eucast.org/clinical\\_breakpoints](https://eucast.org/clinical_breakpoints)

**Standard and High dose antibiotic dosing regimens**

All antibiotic regimens in this document refer to adult doses only, therefore any high dose antibiotic decisions for paediatric patients should be discussed with pharmacist/ Duty microbiologist (via East Surrey Hospital switchboard).

Please be aware that renal and/or hepatic impairment may also influence the dosages of antibiotic required. Contact pharmacist or Duty Microbiologist if any queries or concerns in renal/hepatic impairment and drug interactions.

**Main oral antibiotics affected by new (I) definition – susceptible at increased exposure category**

Antibiotic	Standard dose (S)	High dose 'increased exposure' (I)	Additional information
Amoxicillin	500mg TDS	1g TDS	
Co-amoxiclav	625mg TDS	625mg co-amoxiclav <b>plus</b> 500mg amoxicillin TDS (both antibiotics taken at same time)	
Clarithromycin	250mg–500mg BD	500mg BD	
Erythromycin	500mg QDS	1g QDS	
Doxycycline	loading dose 200mg then 100mg OD	200mg OD	
Flucloxacillin	500mg–1g* QDS	1g QDS*	*PO doses above 500mg can be associated with GI intolerance
Ciprofloxacin	500mg BD	750mg BD	
Levofloxacin	500mg OD/BD	500mg BD	
Clindamycin	300-450mg QDS	Discuss with Duty Microbiologist for an appropriate treatment option.	*PO doses above 450mg can be associated with GI intolerance; therefore switch to IV would be required.
Rifampicin	300mg BD	450–600mg BD	<i>TB</i> dosing: 600mg OD
Co-trimoxazole	960mg BD	Discuss with Duty Microbiologist for an appropriate treatment option.	<i>PCP</i> : much higher doses required. Consult guideline or discuss with Duty microbiologist  Higher doses to be given IV only